2026-04-10

Annual report 2025

”Isofol made clear progress in 2025, focusing on resuming the clinical development of arfolitixorin. After the end of the fiscal year, we reported positive preliminary interim results from the ongoing study. Furthermore, we have had a productive dialogue with regulatory authorities, deepened our collaboration with partner Solasia Pharma K.K., and strengthened our financial position,” says CEO, Petter Segelman Lindqvist.